Biocon Limited

rs,

, 2026 To, The Secretary BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

60%

ogics – Developing cutting-edge biotherapeutics Market cap of $ 2.0 bn4 Market cap of $ 1.4 bn5 60% 2 of Revenue 18% 2 of Revenue 22% 2 of Revenue NASDAQ5 Listed Note: 1. As of 31 March 2026 I 2.

18%

cutting-edge biotherapeutics Market cap of $ 2.0 bn4 Market cap of $ 1.4 bn5 60% 2 of Revenue 18% 2 of Revenue 22% 2 of Revenue NASDAQ5 Listed Note: 1. As of 31 March 2026 I 2. FY26 Revenues. Da

22%

therapeutics Market cap of $ 2.0 bn4 Market cap of $ 1.4 bn5 60% 2 of Revenue 18% 2 of Revenue 22% 2 of Revenue NASDAQ5 Listed Note: 1. As of 31 March 2026 I 2. FY26 Revenues. Data doesn’t conside

₹ 95.4

pany adjustments | 3. For Biocon, as of 26 May 2026, sourced from BSE converted an exchange rate of ₹ 95.4/$ | 4. For Syngene, as of 26 May 2026, sourced from BSE converted an exchange rate of ₹ 95.4 /$. B

52.4%

ene, as of 26 May 2026, sourced from BSE converted an exchange rate of ₹ 95.4 /$. Biocon Ltd has a 52.4% stake in Syngene | 5. For Bicara, Market Cap as of 26 May 2026, from NASDAQ. Biocon Ltd has a 9.8%

9.8%

52.4% stake in Syngene | 5. For Bicara, Market Cap as of 26 May 2026, from NASDAQ. Biocon Ltd has a 9.8% stake in Bicara Therapeutics | 6. As of 31 March 2025 4 Creating strength through innovation, di

₹4,500

usiness in 1 year – among the fastest in industry • Extended maturity profile by 5 years • QIP – ₹4,500 Cr raised to provide exit • Share swap and cash consideration for all to structured instruments

3x

existing minority investors • $800M Bond - 1st Biopharma bond listing in Asia; oversubscribed >3x • Annual savings in interest costs ~₹ • Consolidate 100% of Biocon Biologics 300 Cr. per annu

100%

a bond listing in Asia; oversubscribed >3x • Annual savings in interest costs ~₹ • Consolidate 100% of Biocon Biologics 300 Cr. per annum business(1) 0 84 141 0 162 170 105 174 222 52 1

99.2%

rated business Improved debt maturity profile and stronger balance sheet Note 1: Biocon now holds 99.2% stake in Biocon Biologics, Board has granted in-principle approval to acquire remaining 0.8% 10

0.8%

holds 99.2% stake in Biocon Biologics, Board has granted in-principle approval to acquire remaining 0.8% 10 Acquisition Refinancing - Improved Debt Maturity Profile BBL Original Debt profile (Sep’24)

“FY25 adjusted for gain of $127 mn from sale of business in relation to Metabolics, Oncology, and Critical Care products & one-time generic Lenalidomide sales in the US 27 0 84 141 0 162 170 105 174 222 52 142 166 98 154 82 Financial Highlights – FY26 In ₹ Cr Revenue from Operations Generics Biosimilars CRDMO Others Total Revenue R&D (Net) % of Revenue (Ex.”

Notes

1

Notes

1. Excluding Working Capital Debt 2. Bond: $ 800Mn, Syndicated loan: $ 295Mn and Rolled over Bilateral debt:~$ 30Mn 11 Deleveraged and Strengthened Balance Sheet through Acquisition Re-financing, QIP and EBITDA Growth 0 84 141 0 162 170 105 174 222 52 142 166 98 154 82 Gross Debt Structured debt Other borrowings Cash Net Debt Net Debt / EBITDA 2 Reduction in Leverage : FY23 – FY261 Highlights $ Mn • Structured debt fully redeemed in FY26 2,012 304 1,708 FY23 534 1,478 4.3x1 1,586 - 1,586 FY26 481 1,105 2.7x • FY26: Net Debt/EBITDA at 2.7x : • Deleveraging initiatives • Robust EBITDA growth from the core business • Gross Interest Cost: Reduction driven by deleveraging and refinancing, with full annualized benefits expected from FY’27. Net Debt / EBITDA reduced by ~1.6x due to systemic debt reduction plan and improved EBITDA performance Notes: 1 Jump in leverage in FY23 due to $ 1.2bn term debt and non-convertible instruments availed for acquisition of Viatris’ biosimilars business | 2.